1. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006;368:230–239.

2. Di Ciaula A, Wang DQ, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol 2018;34:71–80.

3. National Institutes of Health Consensus Development Conference Statement on gallstones and laparoscopic cholecystectomy. Am J Surg 1993;165:390–398.

4. Lammert F, Sauerbruch T. Mechanisms of disease: the genetic epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol 2005;2:423–433.

5. Yoo EH, Lee SY. The prevalence and risk factors for gallstone disease. Clin Chem Lab Med 2009;47:795–807.

6. Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system. Gallstone disease. BMJ 2001;322:91–94.

7. Lammert F, Neubrand MW, Bittner R, et al. [S3-guidelines for diagnosis and treatment of gallstones. German Society for Digestive and Metabolic Diseases and German Society for Surgery of the Alimentary Tract]. Z Gastroenterol 2007;45:971–1001German.

8. Higashizono K, Nakatani E, Hawke P, Fujimoto S, Oba N. Risk factors for gallstone disease onset in Japan: findings from the Shizuoka study, a population-based cohort study. PLoS One 2022;17:e0274659.

9. Trotman BW. Pigment gallstone disease. Gastroenterol Clin North Am 1991;20:111–126.

10. Huang J, Chang CH, Wang JL, et al. Nationwide epidemiological study of severe gallstone disease in Taiwan. BMC Gastroenterol 2009;9:63.

11. Kim JW, Oh HC, Do JH, Choi YS, Lee SE. Has the prevalence of cholesterol gallstones increased in Korea? A preliminary single-center experience. J Dig Dis 2013;14:559–563.

12. Yoo EH, Oh HJ, Lee SY. Gallstone analysis using Fourier Transform Infrared spectroscopy (FT-IR). Clin Chem Lab Med 2008;46:376–381.

13. World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific perspective : redefining obesity and its treatment. Sydney: Health Communications Australia, 2000. 14. Park HS, Park CY, Oh SW, Yoo HJ. Prevalence of obesity and metabolic syndrome in Korean adults. Obes Rev 2008;9:104–107.

15. Li H, Zhang C. Association between triglyceride-glucose index and gallstones: a cross-sectional study. Sci Rep 2024;14:17778.

16. Vezina WC, Paradis RL, Grace DM, et al. Increased volume and decreased emptying of the gallbladder in large (morbidly obese, tall normal, and muscular normal) people. Gastroenterology 1990;98:1000–1007.

17. Bonfrate L, Wang DQ, Garruti G, Portincasa P. Obesity and the risk and prognosis of gallstone disease and pancreatitis. Best Pract Res Clin Gastroenterol 2014;28:623–635.

18. Cortés VA, Barrera F, Nervi F. Pathophysiological connections between gallstone disease, insulin resistance, and obesity. Obes Rev 2020;21:e12983.

19. Yang YS, Han BD, Han K, Jung JH, Son JW, Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity. Obesity Fact Sheet in Korea, 2021: trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr 2022;31:169–177.

20. Liu T, Wang W, Ji Y, et al. Association between different combination of measures for obesity and new-onset gallstone disease. PLoS One 2018;13:e0196457.

21. Dubrac S, Parquet M, Blouquit Y, et al. Insulin injections enhance cholesterol gallstone incidence by changing the biliary cholesterol saturation index and apo A-I concentration in hamsters fed a lithogenic diet. J Hepatol 2001;35:550–557.

22. Choi DH, Hur YI, Kang JH, et al. Usefulness of the waist circumference-to-height ratio in screening for obesity and metabolic syndrome among Korean children and adolescents: Korea National Health and Nutrition Examination Survey, 2010-2014. Nutrients 2017;9:256.

23. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev 2012;13:275–286.

24. Wang HH, Portincasa P, Liu M, Wang DQ. Effects of biliary phospholipids on cholesterol crystallization and growth in gallstone formation. Adv Ther 2023;40:743–768.

25. Zhang C, Dai W, Yang S, Wu S, Kong J. Resistance to cholesterol gallstone disease: hepatic cholesterol metabolism. J Clin Endocrinol Metab 2024;109:912–923.

26. Shen WJ, Azhar S, Kraemer FB. SR-B1: a unique multifunctional receptor for cholesterol influx and efflux. Annu Rev Physiol 2018;80:95–116.

27. Jiang ZY, Parini P, Eggertsen G, et al. Increased expression of LXRα, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients. J Lipid Res 2008;49:464–472.